Bright Minds Biosciences (DRUG) Q1 2026 Earnings
DRUG·Reported May 20, 2026·Before market open
Diluted EPS came in at $-0.80 (-50.9% YoY), beat the $-1.17 consensus by $0.37.
Diluted EPS
$-0.80beat by $0.37
Consensus: $-1.17
SEC Filings
Earnings release8-K not filed yet
Quarterly report10-Q / 10-K not filed yet
Filings will appear here once submitted to SEC EDGAR.
Q1 2026 Earnings FAQ
Common questions about Bright Minds Biosciences's Q1 2026 earnings report.
Bright Minds Biosciences (DRUG) reported Q1 2026 earnings on May 20, 2026 before market open.
Bright Minds Biosciences reported diluted EPS of $-0.80 for Q1 2026.
EPS beat the consensus estimate of $-1.17 by $0.37.
Compared to the same quarter a year prior, diluted EPS declined 50.9% from $-0.53.